Daiwa Securities Group Inc. Sells 600 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Daiwa Securities Group Inc. decreased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 71.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 237 shares of the specialty pharmaceutical company’s stock after selling 600 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Jazz Pharmaceuticals were worth $26,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc raised its position in shares of Jazz Pharmaceuticals by 13,450.0% in the second quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock valued at $29,000 after buying an additional 269 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in Jazz Pharmaceuticals during the 2nd quarter worth $29,000. EverSource Wealth Advisors LLC raised its holdings in Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 97 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after acquiring an additional 116 shares during the period. Finally, Gladius Capital Management LP acquired a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth $33,000. Institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. The trade was a 8.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the sale, the executive vice president now owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,110 shares of company stock worth $720,160 over the last three months. Company insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $121.59 on Monday. The company has a market capitalization of $7.35 billion, a P/E ratio of 17.13, a PEG ratio of 1.03 and a beta of 0.57. The company has a fifty day moving average price of $114.87 and a 200-day moving average price of $111.13. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $134.17.

Analysts Set New Price Targets

JAZZ has been the subject of a number of analyst reports. JPMorgan Chase & Co. boosted their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Robert W. Baird upped their price target on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. Cantor Fitzgerald reiterated an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Royal Bank of Canada boosted their price objective on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, October 23rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, November 21st. Three investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.33.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.